NeoChord has announced that it has received the CE mark for its technology that allows the implantation of artificial chordae tendinae, a proven technique for the repair of mitral valve prolapse, via a transapical, off-pump procedure
The Company also announced that it has started the 50-patient “TACT” (Transapical Artificial Chordae Tendinae) Registry, with first commercial European procedures scheduled for first quarter of 2013. Initial TACT Registry procedures will be proctored by Joerg Seeburger (Leipzig Herzzentrum), Giovanni Speziali (University of Pittsburgh Medical Center) and Richard Daly (Mayo Clinic).
“Receiving CE marking for the NeoChord device for implantation of artificial chordae tendinae via a transapical, off-pump procedure and beginning the Tact Registry are meaningful steps forward in the treatment of patients with severe mitral regurgitation,” said Speziali, the primary inventor of NeoChord’s technology. “We are pleased with the short- and medium-term clinical outcomes to date using NeoChord’s technology to treat patients suffering from mitral regurgitation. The NeoChord procedure allows patients an alternative to still undergo a quality repair without enduring the rigours of traditional treatment via open-chest surgery performed on a stopped heart.”
